<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c),
AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)
(Amendment No. ______________)(1)
Boston Life Sciences, Inc.
(Name of Issuer)
Common Stock, par value $.01 per share
(Title of Class of Securities)
100843 40 8
(CUSP Number)
February 5, 1999
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which Schedule is
filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
- --------
(1)The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities and Exchange Act
of 1934 ("Act") or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE> 2
- --------------------- ------------------------
CUSIP NO. 100843 40 8 13G PAGE 2 OF 6 PAGES
- --------------------- ------------------------
<TABLE>
<CAPTION>
<S> <C>
===================================================================================================================================
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
The Tail Wind Fund, Ltd.
- -----------------------------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
- -----------------------------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- -----------------------------------------------------------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
British Virgin Islands
- -----------------------------------------------------------------------------------------------------------------------------------
NUMBER OF SHARES 5 SOLE VOTING POWER 744,818
-----------------------------------------------------------------------------
BENEFICIALLY
OWNED BY EACH 6 SHARED VOTING POWER 0
-----------------------------------------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER 744,818
-----------------------------------------------------------------------------
PERSON WITH 8 SHARED DISPOSITIVE POWER 0
- -----------------------------------------------------------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
744,818
- -----------------------------------------------------------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES* [ ]
- -----------------------------------------------------------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.35%
- -----------------------------------------------------------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
OO
===================================================================================================================================
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE> 3
- --------------------- ------------------------
CUSIP NO. 100843 40 8 13G PAGE 3 OF 6 PAGES
- --------------------- ------------------------
ITEM 1(a). NAME OF ISSUER:
Boston Life Sciences, Inc.
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
31 Newbury Street, Suite 300
Boston, MA 02116
ITEM 2(a). NAME OF PERSON FILING:
The Tail Wind Fund, Ltd.
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Windermere House
404 East Bay Street
P.O. Box SS-5539
Nassau, Bahamas
ITEM 2(c). CITIZENSHIP:
British Virgin Islands
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
This statement relates to the shares of common stock, par value
$0.01 per share (the "Common Stock"), of Boston Life Sciences, Inc.,
a Delaware corporation (the "Company").
ITEM 2(e). CUSIP NUMBER:
100843 40 8
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b), OR 13d-2(b),
CHECK WHETHER THE PERSON FILING IS A:
(a) [ ] Broker or dealer registered under Section 15 of
the Exchange Act.
(b) [ ] Bank as defined in Section 3(a)(6) of the
Exchange Act.
<PAGE> 4
- --------------------- ------------------------
CUSIP NO. 100843 40 8 13G PAGE 4 OF 6 PAGES
- --------------------- ------------------------
(c) [ ] Insurance company as defined in Section 3(a)(19)
of the Exchange Act.
(d) [ ] Investment company registered under Section 8 of
the Investment Company Act.
(e) [ ] An investment adviser in accordance with Rule
13d-1(b)(1)(ii)(E);
(f) An employee benefit plan or endowment fund in
accordance with Rule 13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in
accordance with Rule 13d-1(b)(1)(ii)(G);
(h) [ ] A savings association as defined in Section 3(b)
of the Federal Deposit Insurance Act;
(i) [ ] A church plan that is excluded from
the definition of an investment company under Section
3(c)(14) of the Investment Company Act;
(j) [ ] Group, in accordance with Rule
13d-1(b)(1)(ii)(J).
If this statement is filed pursuant to Rule 13d-1(c), check
this box. [X]
ITEM 4. OWNERSHIP.
(a) Amount beneficially owned:
744,818 shares, which includes 97,150 shares that may be acquired
upon exercise of certain warrants.
(b) Percent of class:
5.35%
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: 744,818
(ii) Shared power to vote or to direct the vote: 0
<PAGE> 5
- --------------------- ------------------------
CUSIP NO. 100843 40 8 13G PAGE 5 OF 6 PAGES
- --------------------- ------------------------
(iii) Sole power to dispose or to direct the disposition of: 744,818
(iv) Shared power to dispose or to direct the disposition of: 0
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
Not applicable.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Not applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
None.
ITEM 10. CERTIFICATION.
"By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not
held for the purpose of and with the effect of changing or influencing the
control of the issuer of the securities and were not acquired and are not
held in connection with or as a participant in any transaction having that
purpose or effect."
<PAGE> 6
- --------------------- ------------------------
CUSIP NO. 100843 40 8 13G PAGE 6 OF 6 PAGES
- --------------------- ------------------------
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
February 26, 1999
------------------------------------------
(Date)
The Tail Wind Fund, Ltd.
------------------------------------------
By:/s/ Jason McCarroll
---------------------------------------
Jason McCarroll, Authorized Signatory
By:/s/ Michael Darville
---------------------------------------
Michael Darville, Vice President
and Director
